0HIY Stock Overview
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Atara Biotherapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.70 |
52 Week High | US$3.08 |
52 Week Low | US$0.20 |
Beta | 0.71 |
1 Month Change | -12.46% |
3 Month Change | 20.15% |
1 Year Change | -76.36% |
3 Year Change | -95.29% |
5 Year Change | n/a |
Change since IPO | -98.12% |
Recent News & Updates
Recent updates
Shareholder Returns
0HIY | GB Biotechs | GB Market | |
---|---|---|---|
7D | 2.8% | 1.7% | 2.2% |
1Y | -76.4% | -27.5% | 3.7% |
Return vs Industry: 0HIY underperformed the UK Biotechs industry which returned -27.5% over the past year.
Return vs Market: 0HIY underperformed the UK Market which returned 3.7% over the past year.
Price Volatility
0HIY volatility | |
---|---|
0HIY Average Weekly Movement | 27.1% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HIY's share price has been volatile over the past 3 months.
Volatility Over Time: 0HIY's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 317 | Pascal Touchon | https://www.atarabio.com |
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
Atara Biotherapeutics, Inc. Fundamentals Summary
0HIY fundamental statistics | |
---|---|
Market cap | US$71.35m |
Earnings (TTM) | -US$290.25m |
Revenue (TTM) | US$4.54m |
15.7x
P/S Ratio-0.2x
P/E RatioIs 0HIY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HIY income statement (TTM) | |
---|---|
Revenue | US$4.54m |
Cost of Revenue | US$5.73m |
Gross Profit | -US$1.18m |
Other Expenses | US$289.06m |
Earnings | -US$290.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.85 |
Gross Margin | -26.07% |
Net Profit Margin | -6,390.31% |
Debt/Equity Ratio | 0% |
How did 0HIY perform over the long term?
See historical performance and comparison